Journal of Critical Care Medicine最新文献

{"title":"Successful Extracorporeal Blood Purification Therapy using Double Haemoadsorption Device in Severe Endotoxin Septic Shock: A Case Report.","authors":"Stefano Ferraro,&nbsp;Stefania Bianzina,&nbsp;Sonila Mocka,&nbsp;Francesca Cappadona,&nbsp;Giovanni Battista Traverso,&nbsp;Fabio Massarino,&nbsp;Pasquale Esposito","doi":"10.2478/jccm-2022-0028","DOIUrl":"https://doi.org/10.2478/jccm-2022-0028","url":null,"abstract":"<p><strong>Introduction: </strong>In patients admitted to the Intensive Care Unit (ICU), sepsis can lead to acute kidney injury (AKI), which may require the initiation of continuous renal replacement therapy (CRRT) in 15-20% of cases. There is no consensus about the best extracorporeal treatment to choose in septic patients with AKI.</p><p><strong>Case presentation: </strong>We describe the case of a 70-year-old woman admitted to the ICU with a severe endotoxin septic shock due to Neisseria meningitidis serogroup C. Despite prompt medical intervention, including fluid resuscitation, high dose vasopressor, inotrope support, and broad-spectrum antimicrobial treatment, in a few hours patient's haemodynamic worsened and she developed multi-organ failure, including severe AKI, requiring CRRT. So, continuous veno-venous haemodiafiltration was started, using an oXiris® haemodiafilter set, in series with an adsorber device (CytoSorb®). After 48 hours of this combined extracorporeal treatment, haemodynamic parameters improved, allowing a significant reduction of the vasoactive therapy, with a concomitant decrease in endotoxin and inflammatory markers serum levels. In the following days patient's conditions still improved and renal function recovered.</p><p><strong>Conclusions: </strong>Timely extracorporeal blood purification therapy, using a double haemoadsorption device, may be effective in the management of severe septic shock.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In between Opioid Crisis and the Need to Treat Pain, where do we Stand?","authors":"Daniela Ionescu,&nbsp;Simona Margarit","doi":"10.2478/jccm-2022-0029","DOIUrl":"https://doi.org/10.2478/jccm-2022-0029","url":null,"abstract":"","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Family Burden of ICU Survivors and Correlations with Patient Quality of Life and Psychometric Scores - A Pilot Study.","authors":"Vassiliki Mantziou,&nbsp;Charikleia S Vrettou,&nbsp;Alice G Vassiliou,&nbsp;Stylianos E Orfanos,&nbsp;Anastasia Kotanidou,&nbsp;Ioanna Dimopoulou","doi":"10.2478/jccm-2022-0027","DOIUrl":"https://doi.org/10.2478/jccm-2022-0027","url":null,"abstract":"<p><strong>Introduction: </strong>Post intensive care syndrome (PICS) affects an increasing number of critical illness survivors and their families, with serious physical and psychological sequelae. Since little is known about the burden of critical illness on ICU survivor families, we conducted a prospective observational study aiming to assess this, and investigate correlations of the patients' psychometric and health-related quality of life (HRQOL) scores with family burden.</p><p><strong>Materials and methods: </strong>Twenty-nine patients were evaluated in the presence of a family member. Participants were assessed with the use of validated scales for anxiety, depression, post-traumatic stress disorder, cognitive decline, and the family burden scale (FBS).</p><p><strong>Results: </strong>High burden was present in 27.6% of family members. Statistically significant correlations were observed between the FBS score and trait anxiety, depression, and the physical and psychological components of HRQOL.</p><p><strong>Conclusions: </strong>Our results suggest that family burden following critical illness is common, suggesting that its assessment should be incorporated in the evaluation of PICS-family in large observational studies.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability of Steroid Prescription for COVID-19 Associated Pneumonia in Real-Life, Non-Trial Settings.","authors":"Rashid Nadeem,&nbsp;Islam Bon,&nbsp;Doaa Algohary,&nbsp;Mohd Kafeel Khan,&nbsp;Nilesh Gundawar,&nbsp;Mohammed Abdullah,&nbsp;Ekta Sharma,&nbsp;Moatz Galal Elzeiny,&nbsp;Mayada Mahmoud,&nbsp;Ashraf Elhoufi,&nbsp;Yusra Omar Alshaikh Sayed Ahmed,&nbsp;Gloria Gheno,&nbsp;Maged Talaat Salama Khalil,&nbsp;Tamseela Hussain","doi":"10.2478/jccm-2022-0025","DOIUrl":"https://doi.org/10.2478/jccm-2022-0025","url":null,"abstract":"<p><p>The RECOVERY study documented lower 28-day mortality with the use of dexamethasone in hospitalized patients on invasive mechanical ventilation or oxygen with COVID-19 Pneumonia. We aimed to examine the practice patterns of steroids use, and their impact on mortality and length of stay in ICU. We retrospectively examined records of all patients with confirmed Covid 19 pneumonia admitted to the ICU of Dubai hospital from January 1st, 2020 - June 30th, 2020. We assigned patients to four groups (No steroids, low dose, medium dose, and high dose steroids). The primary clinical variable of interest was doses of steroids. Secondary outcomes were 28-day mortality and length of stay in ICU\". We found variability in doses of steroid treatment. The most frequently used dose was the high dose. Patients who survived were on significantly higher doses of steroids and had significantly longer stays in ICU. The prescription of steroids in Covid-19 ARDS is variable. The dose of steroids impacts mortality rate and length of stay in ICU, although patients treated with high dose steroids seem to stay more days in ICU.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation.","authors":"Nobuhisa Hirayu,&nbsp;Atsuo Nakamura,&nbsp;Toshio Morita,&nbsp;Osamu Takasu","doi":"10.2478/jccm-2022-0021","DOIUrl":"https://doi.org/10.2478/jccm-2022-0021","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with severe coronavirus disease 2019 (COVID-19) receiving ventilation or pulmonary support via veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be infected with drug-resistant bacteria. When introducing VV-ECMO, the changes in serum antibiotic concentration should be considered due to an increased volume of distribution (Vd). However, no pharmacokinetic study has assessed teicoplanin (TEIC) treatment in patients with COVID-19 receiving VV-ECMO.</p><p><strong>Case presentation: </strong>A 71-year-old man diagnosed with COVID-19 visited a primary hospital. His oxygenation conditions worsened despite treatment with favipiravir and methylprednisolone as well as oxygen therapy. After his transfer to our center, tracheal intubation and steroid pulse therapy were initiated. Seven days after admission, VV-ECMO was performed. TEIC was administered for secondary bacterial infection. The serum TEIC concentration remained within the therapeutic range, indicating that VV-ECMO did not significantly affect TEIC pharmacokinetics. VV-ECMO was discontinued 17 days after admission. However, he developed multi-organ disorder and died 42 days after admission.</p><p><strong>Conclusion: </strong>As TEIC prevents viral invasion, it may be used with ECMO in patients with COVID-19 requiring ventilation; however, the altered pharmacokinetics of TEIC, such as increased Vd, should be considered. Therefore, TEIC pharmacokinetics in VV-ECMO should be assessed in future studies with an appropriate number of patients.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Lethal Caffeine Overdose with Haemodialysis: A Case Report and Review.","authors":"Christian C Toquica Gahona,&nbsp;Ashwin Kodagnur Bharadwaj,&nbsp;Monarch Shah,&nbsp;Umesh Bhagat,&nbsp;Paul Sterman,&nbsp;William Vasquez","doi":"10.2478/jccm-2022-0019","DOIUrl":"https://doi.org/10.2478/jccm-2022-0019","url":null,"abstract":"<p><p>Caffeine, chemically 1,3,7-trimethylxanthine, is the most widely consumed central nervous system stimulant in the world with pleiotropic effects on the cardiovascular, pulmonary, and renal systems. The advent of over the counter (OTC) caffeine formulations has opened the window for potential toxicity, either by inadvertent or intentional overdosing. We present the case of a patient who attempted suicide by caffeine overdose treated with emergent haemodialysis and a review of the literature.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective Outcome of HBOT as an Adjuvant Therapy in Patients Diagnosed with COVID-19 in a Tertiary Care Hospital - A Preliminary Study.","authors":"Thiruppathy Palaniappan,&nbsp;Asif Shaikh,&nbsp;Navamani Kirthika","doi":"10.2478/jccm-2022-0008","DOIUrl":"https://doi.org/10.2478/jccm-2022-0008","url":null,"abstract":"<p><strong>Introduction: </strong>Hyperbaricoxygen therapy (HBOT) is breathing100% oxygen in pressurised chamber. This therapy ensures quick oxygen delivery to the bloodstream. In patients with severe COVID-19 pneumonia, progressive hypoxemia occurs. Oxygen therapy hasa significant role in its management.</p><p><strong>Aim of the study: </strong>The objective was to study the efficacy of hyperbaric oxygen therapy (HBOT) as adjuvant therapy for reducing the requirement of additional oxygen supplementationin patients with moderate to severe ARDS diagnosed with COVID-19.</p><p><strong>Methods: </strong>A single-centre prospective pilot cohort study was conducted ata tertiary care hospital from December 2020 to February 2021 over two months. Fifty patients with COVID-19 needingoxygen, satisfying the selection criteria, were included. Hyperbaricoxygen therapy wasgiven to all patients. The patient received30-45 minutes of hyperbaric oxygen with 15 minutes of pressurizing and depressurizing at 2.0 atmosphere absolute (ATA) with or without airbrakesas per the critical care team. Oxygen requirement, PaO2, andcondition at discharge were considered as primary outcome variables.</p><p><strong>Results: </strong>Among the 50 participants studied, the mean age was 53.64±13.26 years. Out of 50 participants, 49(98.00%) had PaO2≤80 mmHg, and one (2.00%) had >80 PaO2. All the participants 50(100%) had PaO2 as 90 mmHg after three sittings.</p><p><strong>Conclusion: </strong>This studyshows promising results in using HBOT to overcome respiratory failure in COVID-19. HBOT reduced the need for oxygen by improving the oxygen saturation levels.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40349986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Metaraminol as a Vasopressor in Critically Unwell Patients: A Narrative Review and a Survey of UK Practice.","authors":"Lina Grauslyte,&nbsp;Nathalie Bolding,&nbsp;Mandeep Phull,&nbsp;Tomas Jovaisa","doi":"10.2478/jccm-2022-0017","DOIUrl":"https://doi.org/10.2478/jccm-2022-0017","url":null,"abstract":"<p><strong>Background: </strong>Major international guidelines state that norepinephrine should be used as the first-line vasopressor to achieve adequate blood pressure in patients with hypotension or shock. However, recent observational studies report that in the United Kingdom and Australia, metaraminol is often used as second line medication for cardiovascular support.</p><p><strong>Aim of the study: </strong>The aim of this study was to carry out a systematic review of metaraminol use for management of shock in critically unwell patients and carry out a survey evaluating whether UK critical care units use metaraminol and under which circumstances.</p><p><strong>Methods: </strong>A systematic review literature search was conducted. A short telephone survey consisting of 6 questions regarding metaraminol use was conducted across 30 UK critical care units which included a mix of tertiary and district general intensive care units.</p><p><strong>Results: </strong>Twenty-six of thirty contacted centres responded to our survey. Metaraminol was used in 88% of them in various settings and circumstances (emergency department, theatres, medical emergencies on medical wards), with 67% reporting use of metaraminol infusions in the critical care setting. The systematic literature review revealed several case reports and only two studies conducted in the last 20 years investigating the effect of metaraminol as a stand-alone vasopressor. Both studies focused on different aspects of metaraminol use and the data was incomparable, hence we decided not to perform a meta-analysis.</p><p><strong>Conclusions: </strong>Metaraminol is widely used as a vasopressor inside and outside of the critical care setting in the UK despite limited evidence supporting its safety and efficacy for treating shock. Further service evaluation, observational studies and prospective randomised controlled trials are warranted to validate the role and safety profile of metaraminol in the treatment of the critically unwell patient.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40347790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right Heart Failure as an Atypical Presentation of Chronic Type a Aortic Dissection - Multimodality Imaging for Accurate Diagnosis and Treatment. A Case Report and Mini-review of Literature.","authors":"Ioan Tilea,&nbsp;Robert Adrian Dumbrava,&nbsp;Alexandra Mihaela Ratiu,&nbsp;Marius Mihai Harpa,&nbsp;Cosmin Marian Banceu,&nbsp;Dorina Nastasia Petra,&nbsp;Horatiu Suciu","doi":"10.2478/jccm-2022-0016","DOIUrl":"https://doi.org/10.2478/jccm-2022-0016","url":null,"abstract":"<p><strong>Background: </strong>An intrapericardial organized haematoma secondary to chronic type A aortic dissection is an extremely rare cause of right heart failure. Imaging studies are essential in recognising and diagnosis of this distinctive medical condition and guiding the anticipated treatment.</p><p><strong>Case presentation: </strong>A 70-year-old male patient was admitted for progressive symptoms of right heart failure. His cardiovascular history exposed an aortic valve replacement 22 years before with a Medtronic Hall 23 tilting valve with no regular follow-up. Classical signs of congestion were recognized at physical examination. Transthoracic two-dimensional echocardiography and thoraco-abdominal computed tomography angiography, as essential parts of multimodality imaging algorithm, established the underlying cause of right heart failure. Under total cardiopulmonary bypass and cardiac arrest, surgical removal of the haematoma and proximal repair of the ascending aorta with a patient-matched vascular graft were successfully performed. The patient was discharged in good condition with appropriate pharmacological treatment, guideline-directed; no imagistic signs of acute post-surgery complications were ascertained.</p><p><strong>Conclusion: </strong>This paper highlights the importance of recognizing and providing a timely clinical and imagistic diagnosis of this very rare, potentially avoidable cause of right heart failure in patients with previous cardiac surgery.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40347785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Physiological Medicine as the Future of Intensive Care Medicine.","authors":"Leonard Azamfirei","doi":"10.2478/jccm-2022-0020","DOIUrl":"https://doi.org/10.2478/jccm-2022-0020","url":null,"abstract":"","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40347788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}